Published in Behav Brain Res on May 09, 2009
Sex differences in animal models of psychiatric disorders. Br J Pharmacol (2014) 1.15
Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology (2010) 1.12
Enduring increases in anxiety-like behavior and rapid nucleus accumbens dopamine signaling in socially isolated rats. Eur J Neurosci (2013) 1.00
Nicotine ameliorates NMDA receptor antagonist-induced deficits in contextual fear conditioning through high-affinity nicotinic acetylcholine receptors in the hippocampus. Neuropharmacology (2010) 0.91
From attention to memory along the dorsal-ventral axis of the medial prefrontal cortex: some methodological considerations. Front Syst Neurosci (2014) 0.90
Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci (2010) 0.88
Dopamine in nucleus accumbens: salience modulation in latent inhibition and overshadowing. J Psychopharmacol (2011) 0.85
Dopamine D1 receptor involvement in latent inhibition and overshadowing. Int J Neuropsychopharmacol (2011) 0.85
Catecholaminergic depletion within the prelimbic medial prefrontal cortex enhances latent inhibition. Neuroscience (2010) 0.84
An Overview of the Association between Schizotypy and Dopamine. Front Psychiatry (2014) 0.84
Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology (2010) 0.84
Reduced dopamine function within the medial shell of the nucleus accumbens enhances latent inhibition. Pharmacol Biochem Behav (2010) 0.83
Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother (2012) 0.81
Reduced activity at the 5-HT(2C) receptor enhances reversal learning by decreasing the influence of previously non-rewarded associations. Psychopharmacology (Berl) (2012) 0.81
Prefrontal cortical GABA transmission modulates discrimination and latent inhibition of conditioned fear: relevance for schizophrenia. Neuropsychopharmacology (2014) 0.81
Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology (2010) 0.80
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) (2010) 0.80
D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors. Neuropsychopharmacology (2013) 0.80
Selective effects of D- and L-govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia. Neuropsychopharmacology (2014) 0.80
ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions. Transl Psychiatry (2013) 0.80
Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning. Behav Brain Res (2012) 0.80
Administration of the Y2 receptor agonist PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia. Neuropsychopharmacology (2013) 0.79
Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Front Psychiatry (2015) 0.79
The learned safety paradigm as a mouse model for neuropsychiatric research. Nat Protoc (2010) 0.78
Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli. Neuropsychopharmacology (2010) 0.78
Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice. Psychopharmacology (Berl) (2015) 0.76
Peripherally administered oxytocin modulates latent inhibition in a manner consistent with antipsychotic drugs. Behav Brain Res (2014) 0.76
Animal Models of Psychosis: Current State and Future Directions. Curr Behav Neurosci Rep (2014) 0.76
A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res (2013) 0.76
Opposing effects of 5,7-DHT lesions to the core and shell of the nucleus accumbens on the processing of irrelevant stimuli. Int J Neuropsychopharmacol (2011) 0.76
A New Perspective on Delusional States - Evidence for Claustrum Involvement. Front Psychiatry (2015) 0.75
Paradoxical effects of low dose MDMA on latent inhibition in the rat. Neuropharmacology (2012) 0.75
Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms? J Psychopharmacol (2014) 0.75
Chronic Mild Stress Impairs Latent Inhibition and Induces Region-Specific Neural Activation in CHL1-Deficient Mice, a Mouse Model of Schizophrenia. Behav Brain Res (2017) 0.75
A single dose of L-DOPA changes perceptual experiences and decreases latent inhibition in Parkinson's disease. J Neural Transm (Vienna) (2016) 0.75
Tcf4 transgenic female mice display delayed adaptation in an auditory latent inhibition paradigm. Eur Arch Psychiatry Clin Neurosci (2015) 0.75
Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology (Berl) (2010) 0.75
Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology (2008) 3.32
Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry (2010) 1.70
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol (2012) 1.40
The mouse forced swim test. J Vis Exp (2012) 1.24
Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull (2010) 1.13
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl) (2008) 1.02
Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology (2011) 0.97
Abnormal trajectories of neurodevelopment and behavior following in utero insult in the rat. Biol Psychiatry (2011) 0.96
Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology (2009) 0.83
Ovarian hormones modulate 'compulsive' lever-pressing in female rats. Horm Behav (2008) 0.82
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) (2010) 0.80
SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav (2012) 0.78
BioTile, a Perl based tool for the identification of differentially enriched regions in tiling microarray data. BMC Bioinformatics (2013) 0.77